MCID: CRY014
MIFTS: 48

Cryptococcal Meningitis

Categories: Infectious diseases, Neuronal diseases

Aliases & Classifications for Cryptococcal Meningitis

MalaCards integrated aliases for Cryptococcal Meningitis:

Name: Cryptococcal Meningitis 12 15 17
Meningitis, Cryptococcal 44 70
Meningitis Cryptococcal 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0080159
MeSH 44 D016919
UMLS 70 C0085436

Summaries for Cryptococcal Meningitis

Disease Ontology : 12 A fungal meningitis that has material basis in Crypococcus fungal infection.

MalaCards based summary : Cryptococcal Meningitis, also known as meningitis, cryptococcal, is related to meningitis and candidiasis. An important gene associated with Cryptococcal Meningitis is ADA (Adenosine Deaminase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Zidovudine and Lamivudine have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and endothelial, and related phenotypes are hematopoietic system and immune system

Wikipedia : 73 Cryptococcosis, sometimes informally called crypto, is a potentially fatal fungal disease caused by a... more...

Related Diseases for Cryptococcal Meningitis

Diseases related to Cryptococcal Meningitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 420)
# Related Disease Score Top Affiliating Genes
1 meningitis 32.2 VEGFA MBL2 IFNG CSF2 ADA
2 candidiasis 31.0 MBL2 IFNG CSF2
3 acquired immunodeficiency syndrome 30.8 IFNG CSF2 CD4 CCR6 ADA
4 cryptococcosis 30.3 PLB1 MBL2 IFNG CSF2 CD4 CCR6
5 meningoencephalitis 30.3 PLB1 CD4 CCR6
6 sarcoidosis 1 30.3 IFNG CD4 CCR6 ADA
7 human immunodeficiency virus type 1 30.3 SRC MAPK10 IFNG CD4 ADA
8 disease by infectious agent 30.2 MBL2 IFNG CD4 CCR6
9 extrapulmonary tuberculosis 30.2 MBL2 IFNG ADA
10 choroiditis 30.1 VEGFA IFNG CD4
11 anemia, autoimmune hemolytic 30.1 TNFSF13B CD4 CCR6
12 relapsing-remitting multiple sclerosis 30.1 TNFSF13B IFNG CSF2 CCR6
13 nocardiosis 30.0 IFNG CD4
14 pulmonary sarcoidosis 30.0 IFNG CSF2 CCR6
15 miliary tuberculosis 30.0 IFNG CD4 ADA
16 lymphadenitis 30.0 IFNG CD4 CCR6
17 sporotrichosis 29.9 MBL2 IFNG CD4
18 cytomegalovirus retinitis 29.9 IFNG CSF2 CD4
19 histoplasmosis 29.9 IFNG CD4 CCR6
20 bacillary angiomatosis 29.9 VEGFA CD4
21 hypersplenism 29.9 IFNG CSF2 CD4
22 bacterial infectious disease 29.9 MBL2 IFNG CSF2 CD4 CCR6
23 cryptosporidiosis 29.9 MBL2 IFNG CD4
24 immune deficiency disease 29.8 TNFSF13B TNFRSF13B MBL2 IFNG CSF2 CD4
25 fungal meningitis 29.8 PLB1 IFNG CSF2 CD4 CCR6
26 central nervous system tuberculosis 29.8 CD4 ADA
27 nervous system disease 29.8 VEGFA IFNG CSF2 CD4 CCR6
28 hyper ige syndrome 29.7 IFNG CSF2 CCR6
29 chronic mucocutaneous candidiasis 29.7 IFNG CSF2 CD4 CCR6
30 arthritis 29.7 VEGFA TNFSF13B TNFSF13 IFNG CSF2 CCR6
31 syphilis 29.7 IFNG CD4 CCR6
32 coccidioidomycosis 29.7 MBL2 CD4 CCR6
33 cellulitis 29.6 CSF2 CD4 CCR6
34 bacterial pneumonia 29.6 CD4 CCR6 ADA
35 macroglobulinemia 29.6 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B
36 mycobacterium tuberculosis 1 29.6 MBL2 IFNG CD4 CCR6 ADA
37 fungal infectious disease 29.6 PLB1 IFNG CSF2 CD4 CCR6
38 chickenpox 29.6 IFNG CD4 CCR6 ADA
39 exanthem 29.5 VEGFA IFNG CSF2 CD4 CCR6
40 respiratory failure 29.5 VEGFA TNFRSF13B CD4 CCR6
41 leukemia, acute lymphoblastic 29.5 SRC CSF2 CD4 CCR6 ADA
42 connective tissue disease 29.4 VEGFA TNFSF13B TNFSF13 IFNG CD4 CCR6
43 multiple sclerosis 29.4 TNFSF13B TNFRSF13C MBL2 IFNG CD4 CCR6
44 central nervous system vasculitis 29.4 VEGFA TNFSF13B IFNG CD4 CCR6
45 opportunistic mycosis 29.2 PLB1 IFNG CSF2 CD4 CCR6
46 thrombocytopenia 29.2 TNFSF13B TNFRSF13C TNFRSF13B SRC MBL2 IFNG
47 human immunodeficiency virus infectious disease 29.2 MBL2 IFNG CSF2 CD4 CCR6 ADA
48 myeloma, multiple 28.7 VEGFA TNFSF13B TNFRSF17 SRC CSF2 CD4
49 leukemia, chronic lymphocytic 28.5 VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
50 systemic lupus erythematosus 28.4 VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B

Comorbidity relations with Cryptococcal Meningitis via Phenotypic Disease Network (PDN):


Acute Cystitis Cryptococcosis
Deficiency Anemia

Graphical network of the top 20 diseases related to Cryptococcal Meningitis:



Diseases related to Cryptococcal Meningitis

Symptoms & Phenotypes for Cryptococcal Meningitis

MGI Mouse Phenotypes related to Cryptococcal Meningitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.3 ADA ARRB2 CCR6 CD4 CSF2 EFS
2 immune system MP:0005387 10.16 ADA ARRB2 CCR6 CD4 CSF2 EFS
3 homeostasis/metabolism MP:0005376 10.13 ADA ARRB2 CCR6 CD4 CSF2 FCGR2B
4 normal MP:0002873 9.81 ADA CCR6 CD4 FCGR2B IFNG TNFRSF17
5 renal/urinary system MP:0005367 9.56 ADA CSF2 EFS FCGR2B IFNG MBL2
6 respiratory system MP:0005388 9.23 ADA ARRB2 CSF2 EFS FCGR2B IFNG

Drugs & Therapeutics for Cryptococcal Meningitis

Drugs for Cryptococcal Meningitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zidovudine Approved Phase 4 30516-87-1 35370
2
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
3
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
4
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
5
Nevirapine Approved Phase 4 129618-40-2 4463
6
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
7
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
8 Reverse Transcriptase Inhibitors Phase 4
9 Anti-Retroviral Agents Phase 4
10 Antiviral Agents Phase 4
11 Anti-HIV Agents Phase 4
12 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
13 Liver Extracts Phase 4
14
Sertraline Approved Phase 3 79617-96-2 68617
15
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
16
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
17
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
18
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 14956 5280965
19 Neurotransmitter Agents Phase 3
20 Antidepressive Agents Phase 3
21 Psychotropic Drugs Phase 3
22 Serotonin Uptake Inhibitors Phase 3
23 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
24 Hormone Antagonists Phase 2, Phase 3
25 Hormones Phase 2, Phase 3
26 Anti-Infective Agents Phase 2, Phase 3
27 Antifungal Agents Phase 2, Phase 3
28 Liposomal amphotericin B Phase 2, Phase 3
29 Amebicides Phase 2, Phase 3
30 Antiparasitic Agents Phase 2, Phase 3
31 Antiprotozoal Agents Phase 2, Phase 3
32 Anti-Bacterial Agents Phase 2, Phase 3
33
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
34
Itraconazole Approved, Investigational Phase 2 84625-61-6 55283
35
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
36
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
37
Tamoxifen Approved Phase 2 10540-29-1 2733526
38
Flucytosine Approved, Investigational Phase 2 2022-85-7 3366
39
Efungumab Investigational Phase 2 762260-74-2
40
Hydroxyitraconazole Phase 2 108222
41 Interferon-gamma Phase 2
42 interferons Phase 2
43 Antiemetics Phase 2
44 glucocorticoids Phase 2
45 Antineoplastic Agents, Hormonal Phase 2
46 Anti-Inflammatory Agents Phase 2
47 Estrogen Receptor Modulators Phase 2
48 Estrogens Phase 2
49 Estrogen Receptor Antagonists Phase 2
50 Estrogen Antagonists Phase 2

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
2 Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis Completed NCT01075152 Phase 4 efavirenz
3 Operational Research for Cryptococcal Antigen Screening to Improve ART Survival Completed NCT01535469 Phase 4 Fluconazole
4 A Randomized Clinical Trial of Immediate Versus Standard Antiretroviral Therapy for HIV-infected Adults Presenting With Cryptococcal Meningitis Completed NCT00976040 Phase 4
5 Evaluation of World Health Organization (WHO) Recommendations on Test and Treat Strategy, Managing Advanced HIV Disease and Rapid Initiation of ART Among People Living With HIV in Nepal: A Cluster Randomized Trial. Completed NCT03723525 Phase 4
6 Prospective Pilot Study to Evaluate a Standardized Management of Cryptococcal Meningitis in Patients Infected With HIV in Sub-Saharan Africa Involving an Initial Combination Therapy With Fluconazole and Flucytosine in High Doses, Complemented by Repeat Lumbar Punctures Unknown status NCT01715922 Phase 2, Phase 3 Fluconazole;Flucytosine
7 Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis Completed NCT01802385 Phase 3 Sertraline
8 Comparison of Fluconazole (UK-49,858) and Amphotericin B for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00001017 Phase 3 Fluconazole;Amphotericin B
9 Rapid Diagnostic Tests in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases in Patients With Neurological Disorders in Rural Hospitals of Bandundu,Democratic Republic of Congo Completed NCT01589289 Phase 3
10 Evaluation of CrAg Screening With Enhanced Antifungal Therapy for Asymptomatic CrAg+ Persons Recruiting NCT03945448 Phase 2, Phase 3 Single dose liposomal Amphotericin and Fluconazole;Fluconazole
11 Antifungal Treatment of Cryptococcal Meningitis Not yet recruiting NCT04140461 Phase 3 Amphotericin B;Flucytosine
12 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase II Study of the Safety and Antifungal Activity of Subcutaneous Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) in Conjunction With Standard Therapy in Patients With Acute Cryptococcal Meningitis Completed NCT00012467 Phase 2 Itraconazole;Flucytosine;Fluconazole;Amphotericin B;Interferon gamma-1b
13 Dexamethasone in Cryptococcal Meningitis Completed NCT00000776 Phase 2 Flucytosine;Fluconazole;Amphotericin B;Dexamethasone
14 A Phase II Randomized Trial of Amphotericin B Alone or Combined With Fluconazole in the Treatment of AIDS-Associated Cryptococcal Meningitis Completed NCT00145249 Phase 2 Amphotericin B;Fluconazole
15 A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis Completed NCT03112031 Phase 2 Tamoxifen;Amphotericin B;Fluconazole
16 A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis Completed NCT00885703 Phase 1, Phase 2 Fluconazole;Amphotericin B
17 Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial Recruiting NCT04031833 Phase 1, Phase 2 MAT2203;Amphotericin B
18 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Terminated NCT00324025 Phase 2 Mycograb;placebo
19 A Multicenter, Randomized Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Terminated NCT00847678 Phase 2
20 SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy Completed NCT00000677 Phase 1 SCH 39304
21 Phase I Study to Evaluate the Safety and Tolerance of RMP-7 Administered With Amphotericin B to Patients With HIV Infection and Cryptococcal Meningitis Completed NCT00002316 Phase 1 Lobradimil;Amphotericin B
22 Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report From June 2015 to June 2016 Completed NCT02955862 Phase 1
23 Evaluation of a Public Health Strategy to Improve Survival of HIV Infected Patients Unknown status NCT02334670 Fluconazole
24 Vietnam Cryptococcal Retention in Care Study (CRICS) - Version 2.1 Unknown status NCT03267407
25 A Randomized Study to Evaluate the Safety and Efficacy of Liposomal Amphotericin B and Amphotericin B Deoxycholate With or Without Flucytosine Followed by Fluconazole, for the Treatment of Cryptococcal Meningitis Unknown status NCT02136030 Liposomal amphotericin B;Amphotericin B-deoxycholate
26 Implementation and Evaluation of a Screening Strategy to Reduce Morbidity and Mortality Due to Cryptoccocal Meningo-encephalitis in ART Naive AIDS Patients With <100 CD4 Count at the Day Hospital of the Yaounde Central Hospital, Cameroon Unknown status NCT02624453 Fluconazole;Antiretroviral therapy
27 The CryptoART Study: Decreasing Mortality Associated With Initiation of Antiretroviral Therapy in Sub-Saharan Africa Through Early Detection and Prevention of Cryptococcal Disease Completed NCT02434172
28 Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis. Completed NCT00830856 Fluconazole;Fixed dose - Stavudine, lamivudine and Nevirapine;Fixed dose - Stavudine, Lamivudine, Nevirapine
29 A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis. Completed NCT00002113 Flucytosine;Fluconazole
30 Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome Completed NCT00002019 Amphotericin B, Lipid-based;Amphotericin B
31 A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00000639 Itraconazole;Flucytosine;Fluconazole;Amphotericin B
32 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002075 Flucytosine;Fluconazole;Amphotericin B
33 Multi-Center Evaluation of Fluconazole (UK-49,858) as Treatment for Acute Cryptococcal Meningitis in Patients Who Have Failed to Respond or Have Experienced Unacceptable Toxicity During Treatment With Amphotericin B Completed NCT00002306 Fluconazole
34 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002305 Flucytosine;Fluconazole;Amphotericin B
35 Double Blind Placebo Controlled Study of Fluconazole (UK-49,858) for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002294 Fluconazole
36 An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002077 Fluconazole
37 Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002076 Fluconazole
38 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002074 Fluconazole;Amphotericin B
39 A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002068 Fluconazole;Amphotericin B
40 Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002040 Fluconazole
41 Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00000708 Flucytosine;Fluconazole;Amphotericin B
42 Clinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral Therapy Completed NCT02098525
43 Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis in Patients With HIV Infection Recruiting NCT04532463 Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week
44 Integrating the Diagnosis and Management of HIV-associated Central Nervous System (CNS) Infections Into Routine Health Services in Low and Middle Income Countries (LMICs) Recruiting NCT03226379
45 The Lived Experience of Participants in an African Randomised Trial Recruiting NCT04296292
46 Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia Recruiting NCT00867269
47 The Effect and Safety of Three Initial Introduction Treatments on HIV-infected Patients With Cryptococcal Meningitis: A Multi-center, Random and Prospective Study Active, not recruiting NCT04072640 Early Phase 1 Voriconazole 200mg;amphotericin B deoxycholate (0.4-0.5mg/kg/d);Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)

Search NIH Clinical Center for Cryptococcal Meningitis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Fluconazole
Flucytosine

Cochrane evidence based reviews: meningitis, cryptococcal

Genetic Tests for Cryptococcal Meningitis

Anatomical Context for Cryptococcal Meningitis

MalaCards organs/tissues related to Cryptococcal Meningitis:

40
Kidney, Liver, Endothelial, Brain, Bone Marrow, Eye, Pituitary

Publications for Cryptococcal Meningitis

Articles related to Cryptococcal Meningitis:

(show top 50) (show all 2536)
# Title Authors PMID Year
1
Cerebrospinal fluid adenosine deaminase activity for the diagnosis of tuberculous meningitis in adults. 61 54
17333738 2006
2
Cerebrospinal fluid adenosine deaminase levels in a patient with cryptococcal meningitis. 61 54
1457651 1992
3
[Cryptococcal meningitis in patients with AIDS: combined treatment with amphotericin B and fluconazole, and high levels of adenosine deaminase in cerebrospinal fluid]. 61 54
1620927 1992
4
Sustained intrathecal delivery of amphotericin B using an injectable and biodegradable thermogel. 61
33657949 2021
5
The role of optic nerve sheath diameter ultrasound in brain infection. 61
33728383 2021
6
Delays in lumbar puncture are independently associated with mortality in cryptococcal meningitis: a nationwide study. 61
33661068 2021
7
Quality of life and associated factors among HIV positive patients after completion of treatment for Cryptococcal meningitis. 61
33657099 2021
8
HIV-Associated Cryptococcal Meningitis Patients Treated with Amphotericin B Deoxycholate Plus Flucytosine under Routine Care Conditions in a Referral Center in São Paulo, Brazil. 61
33258083 2021
9
Cryptococcal meningitis in non-HIV patients in the State of Amazonas, Northern Brazil. 61
33025379 2021
10
A Descriptive Analysis of Dried Blood Spot Adherence Testing Among Ugandans with HIV Presenting with Cryptococcal Meningitis. 61
33677986 2021
11
Predictors of in-hospital mortality among HIV-positive patients presenting with an acute illness to the emergency department. 61
33792151 2021
12
Cryptococcal meningitis presented as sudden hearing loss: A case study. 61
33276295 2021
13
Cryptococcus neoformans-Infected Macrophages Release Proinflammatory Extracellular Vesicles: Insight into Their Components by Multi-omics. 61
33785616 2021
14
Cryptococcus neoformans-astrocyte interactions: effect on fungal blood brain barrier disruption, brain invasion, and meningitis progression. 61
33476528 2021
15
The clinical profiles and outcomes of HIV-negative cryptococcal meningitis patients in type II diabetes mellitus. 61
33639846 2021
16
The Optimal Timing of Antiretroviral Therapy Initiation in HIV-Infected Patients with Cryptococcal Meningitis: A Multicenter Prospective Randomized Controlled Trial. 61
33649622 2021
17
Cryptococcal meningitis: a review of cryptococcal antigen screening programs in Africa. 61
32567406 2021
18
Transcription factor-driven alternative localization of Cryptococcus neoformans superoxide dismutase. 61
33567338 2021
19
Cryptococcal Antigen Screening Among Antiretroviral Therapy-Experienced People With HIV With Viral Load Nonsuppression in Rural Uganda. 61
33604402 2021
20
Treatment strategies for cryptococcal infection: challenges, advances and future outlook. 61
33558691 2021
21
Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antigen Receptor T-cell therapy. 61
33303326 2021
22
Clinical features and Outcomes of Cryptococcemia patients with and without HIV infection. 61
33609302 2021
23
Prevalence of Asymptomatic Cryptococcal Antigenemia and Association with Follow-up Risk of Cryptococcal Meningitis and Mortality among HIV Infected Patients in North West India: A Prospective Cohort Study. 61
32860359 2021
24
Impact of biological sex on cryptococcal meningitis mortality in Uganda and South Africa. 61
33399865 2021
25
The epidemiology and clinical spectrum of infections of the central nervous system in adults in north India. 61
33019910 2021
26
Cryptococcal meningitis: a review for emergency clinicians. 61
33420904 2021
27
Ending deaths from HIV-related cryptococcal meningitis by 2030. 61
33271065 2021
28
A case-control study of human immunodeficiency virus-negative patients with cryptococcemia and cryptococcal meningitis in a Chinese tertiary care hospital during 10 years. 61
33472466 2021
29
Prevalence of Cryptococcal Antigen and Outcomes in People With Human Immunodeficiency Virus in Honduras: A Cohort Study. 61
33447630 2021
30
Atypical Presentation of Pediatric Systemic Lupus Erythematosus Complicated by Cryptococcal Meningitis. 61
33628263 2021
31
Comparison of a commercial real-time PCR panel to routine laboratory methods for the diagnosis of meningitis-encephalitis. 61
33472744 2021
32
Cryptococcal Immune Reconstitution Inflammatory Syndrome: From Blood and Cerebrospinal Fluid Biomarkers to Treatment Approaches. 61
33514007 2021
33
Clinical features and treatment outcomes of human immunodeficiency virus-associated cryptococcal meningitis: a 2-year retrospective analysis. 61
33273326 2020
34
Baseline Serum C-Reactive Protein Level Predicts Mortality in Cryptococcal Meningitis. 61
33335936 2020
35
The clinical characteristics and outcome of cryptococcal meningitis with AIDS in a tertiary hospital in China: an observational cohort study. 61
33261581 2020
36
HIV-1C env and gag Variation in the Cerebrospinal Fluid and Plasma of Patients with HIV-Associated Cryptococcal Meningitis in Botswana. 61
33297399 2020
37
Cryptococcal Meningitis: A Rare Complication in HIV-Negative Patients with Nephrotic Syndrome in A Chinese Teaching Hospital. 61
32789738 2020
38
Predictors of postinfectious inflammatory response syndrome in HIV-negative immunocompetent cryptococcal meningitis. 61
33277354 2020
39
Evaluation of antifungal activity of cinnamaldehyde against Cryptococcus neoformans var. grubii. 61
32617865 2020
40
Diagnostic Accuracy of the Biosynex CryptoPS Cryptococcal Antigen Semiquantitative Lateral Flow Assay in Patients with Advanced HIV Disease. 61
33087436 2020
41
Experimental Evolution of Antifungal Resistance in Cryptococcus neoformans. 61
32986290 2020
42
Acute Fluctuant Neurological Symptoms in Stable Chronic Cryptococcus gattii Cryptococcomas: A Novel Disease Complication. 61
33394909 2020
43
AAIT: A novel prognostic model for HIV-negative patients with cryptococcal meningoencephalitis New Scoring Model for Non-HIV Patients with CM. 61
33305321 2020
44
Evaluation of the Dynamiker Cryptococcal Antigen Lateral Flow Assay for the Diagnosis of HIV-Associated Cryptococcosis. 61
33268538 2020
45
Cryptococcus Neoformans Meningitis Cases Among China's HIV-Infected Population may have been Severely Under-Reported. 61
32989582 2020
46
Cerebrospinal Fluid Lactate as a Prognostic Marker of Disease Severity and Mortality in Cryptococcal Meningitis. 61
33249459 2020
47
Triple therapy combined with ventriculoperitoneal shunts can improve neurological function and shorten hospitalization time in non-HIV cryptococcal meningitis patients with increased intracranial pressure. 61
33198666 2020
48
Identifying the patients most likely to die from cryptococcal meningitis - time to move from recognition to intervention. 61
33206149 2020
49
Cerebrospinal fluid microscopy as an index for predicting the prognosis of cryptococcal meningitis patients with and without HIV. 61
33251866 2020
50
Cryptococcal meningitis in an immunocompetent patient. 61
32534877 2020

Variations for Cryptococcal Meningitis

Expression for Cryptococcal Meningitis

Search GEO for disease gene expression data for Cryptococcal Meningitis.

Pathways for Cryptococcal Meningitis

Pathways related to Cryptococcal Meningitis according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
2
Show member pathways
13.74 VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
3
Show member pathways
13.59 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B SRC
4
Show member pathways
13.46 VEGFA TNFSF13B TNFRSF17 TNFRSF13C SRC MAPK10
5
Show member pathways
13.2 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B SRC
6
Show member pathways
13.14 YWHAG TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
7
Show member pathways
13.01 VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
8
Show member pathways
13 YWHAG VEGFA TNFSF13B TNFSF13 SRC MAPK10
9
Show member pathways
12.8 SRC MAPK10 CD4 CCR6 ARRB2
10
Show member pathways
12.75 VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
11
Show member pathways
12.52 VEGFA SRC MAPK10 FCGR2B CSF2
12
Show member pathways
12.26 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B SRC
13 12.25 TNFRSF13C MAPK10 CSF2 CD4
14 12.15 SRC MAPK10 IFNG FCGR2B
15
Show member pathways
12.09 YWHAG TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
16 12.03 VEGFA SRC MAPK10 IFNG
17 11.84 VEGFA TNFSF13B TNFSF13 IFNG CSF2
18
Show member pathways
11.77 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
19 11.75 YWHAG SRC MAPK10 ARRB2
20 11.73 MAPK10 IFNG CSF2
21 11.71 IFNG CD4 CCR6
22
Show member pathways
11.7 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13B
23 11.68 SRC CD4 ARRB2
24 11.67 IFNG CSF2 CD4
25
Show member pathways
11.58 VEGFA IFNG CSF2
26 11.38 TNFRSF13C TNFRSF13B CD4 ADA
27 11.26 TNFRSF13B SRC CSF2
28 11.2 IFNG CSF2 CD4
29 10.99 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B FCGR2B
30 10.79 SRC ARRB2

GO Terms for Cryptococcal Meningitis

Cellular components related to Cryptococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.03 YWHAG VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C
2 plasma membrane GO:0005886 9.47 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B SRC
3 external side of plasma membrane GO:0009897 9.35 TNFRSF13C FCGR2B CD4 CCR6 ADA

Biological processes related to Cryptococcal Meningitis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.07 VEGFA TNFSF13B TNFSF13 TNFRSF17 SRC MAPK10
2 positive regulation of gene expression GO:0010628 10 VEGFA SRC IFNG CSF2 ARRB2
3 adaptive immune response GO:0002250 9.99 TNFRSF17 TNFRSF13C TNFRSF13B IFNG CD4
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 VEGFA SRC CD4 ARRB2
5 positive regulation of protein phosphorylation GO:0001934 9.86 VEGFA IFNG CD4 ARRB2
6 immune system process GO:0002376 9.86 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B SRC
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 VEGFA IFNG CSF2
8 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.76 VEGFA SRC ARRB2
9 positive regulation of T cell proliferation GO:0042102 9.74 TNFSF13B TNFRSF13C CD4
10 T cell costimulation GO:0031295 9.71 TNFSF13B TNFRSF13C SRC
11 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.71 VEGFA SRC CD4 ARRB2
12 immune response GO:0006955 9.7 TNFSF13B TNFSF13 IFNG FCGR2B CSF2 CD4
13 positive regulation of B cell proliferation GO:0030890 9.65 TNFSF13B TNFRSF13C ADA
14 positive regulation of epithelial cell migration GO:0010634 9.63 SRC IFNG CCR6
15 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.62 CSF2 CD4
16 positive regulation of podosome assembly GO:0071803 9.61 SRC CSF2
17 regulation of circadian sleep/wake cycle, sleep GO:0045187 9.55 CSF2 ADA
18 positive regulation of interleukin-23 production GO:0032747 9.52 IFNG CSF2
19 B cell costimulation GO:0031296 9.51 TNFSF13B TNFRSF13C
20 positive regulation of DNA biosynthetic process GO:2000573 9.5 VEGFA SRC ARRB2
21 histamine secretion GO:0001821 9.49 CSF2 ADA
22 positive regulation of germinal center formation GO:0002636 9.43 TNFSF13B ADA
23 tumor necrosis factor-mediated signaling pathway GO:0033209 9.35 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
24 macrophage differentiation GO:0030225 8.92 VEGFA IFNG CSF2 CD4

Molecular functions related to Cryptococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein domain specific binding GO:0019904 9.62 YWHAG SRC EFS ARRB2
2 cytokine activity GO:0005125 9.55 VEGFA TNFSF13B TNFSF13 IFNG CSF2
3 receptor ligand activity GO:0048018 9.43 VEGFA TNFSF13B TNFSF13
4 signaling receptor activity GO:0038023 9.35 TNFRSF17 TNFRSF13C TNFRSF13B CD4 CCR6
5 signaling receptor binding GO:0005102 9.1 TNFSF13B TNFSF13 SRC MBL2 CD4 ARRB2

Sources for Cryptococcal Meningitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....